Department of Clinical Neurosciences
The ESCAPE trial demonstrates the benefits of endovascular treatment compared to conventional treatment for patients with acute ischemic stroke. The patients that were recruited for this study had small infarct core (based on ASPECTS), proximal intracranial occlusion, and the presence of collaterals. The study also ensured that the patients could be treated fast: a target CT to groin puncture of 60 minutes and a target CT to reperfusion of 90 minutes. Furthermore, the study focused on safe and high reperfusion rates.
There were 22 sites from North America, Europe, UK and Asia that recruited patients in ESCAPE. There were 316 patients recruited before the trial was stopped by the DSMB for efficacy.
Click for Trial Registration
|Dr. Michael D. Hill||Dr. Mayank Goyal||Dr. Andrew M. Demchuk|
ESCAPE – The Calgary-led clinical trial that is changing the way the world treats ischemic stroke
|Dr. Michael Hill's ISC ESCAPE Study presentation||Dr. Mayank Goyal addresses the 2015 ISC dinner|
The New England Journal of Medicine:
Please use the links below to learn more about the ESCAPE trial: